Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
Farmers Insurance
McKesson
Deloitte
UBS
Boehringer Ingelheim
Chinese Patent Office
QuintilesIMS
AstraZeneca

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202886

« Back to Dashboard

NDA 202886 describes POTASSIUM CHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Adare Pharms Inc, Amneal Pharms, Anchen Pharms, Glenmark Pharms Ltd, Kremers Urban Pharms, Lupin Ltd, Nesher Pharms, Novel Labs Inc, Paddock Llc, PII, Teva, Tris Pharma Inc, Pharma Res Software, Abraxis Pharm, Akorn, B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Intl Medication, Lilly, Luitpold, Miles, Pharma Serve Ny, Watson Labs, Genus Lifesciences, Copley Pharm, Mylan Pharms Inc, Schering, Sigmapharm Labs Llc, and Icu Medical Inc, and is included in seventy-six NDAs. It is available from forty-nine suppliers. Additional details are available on the POTASSIUM CHLORIDE profile page.

The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and seventy drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.

Summary for 202886

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 202886

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POTASSIUM CHLORIDE potassium chloride CAPSULE, EXTENDED RELEASE;ORAL 202886 ANDA Par Pharmaceutical, Inc. 10370-219 10370-219-05 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10370-219-05)
POTASSIUM CHLORIDE potassium chloride CAPSULE, EXTENDED RELEASE;ORAL 202886 ANDA Par Pharmaceutical, Inc. 10370-219 10370-219-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10370-219-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength8MEQ
Approval Date:Dec 26, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Dec 26, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Queensland Health
Merck
Healthtrust
Cerilliant
Covington
McKinsey
US Army
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot